Market Overview

UPDATE: Jefferies Raises PT to $20 on Arena Pharmaceuticals on Belviq FDA Aproval

Share:
Related ARNA
Arena Pharma Could Be Developing Several Best-In-Class Agents
15 Biggest Mid-Day Gainers For Friday

Jefferies reiterates its Buy rating on Arena Pharmaceuticals (NASDAQ: ARNA) and raises its price target from $9 to $20.

Jefferies says, "Belviq has been approved by the FDA. We believe the Belviq label is a major positive for ARNA, as it lacks a restrictive REMS or cardiovascular monitoring requirements. We remain buyers of ARNA and are raising our price target from $9 to $20."

ARNA closed at $11.39 on Wednesday.

Latest Ratings for ARNA

DateFirmActionFromTo
May 2017Leerink SwannInitiates Coverage OnOutperform
Sep 2016FBR CapitalInitiates Coverage onOutperform
Nov 2013WallachbethInitiates Coverage onBuy

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!